13. Behandling av resektable og potensielt resektable metastaser

Adam, R., Delvart, V., Pascal, G., Valeanu, A., Castaing, D., Azoulay, D., Giacchetti, S., Paule, B., ... Bismuth, H. (2004). Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery, 240(4), 644-57; discussion 657-8.

Adam, R., Piedvache, C., Chiche, L., Adam, J. P., Salamé, E., Bucur, P., Cherqui, D., Scatton, O., ... Gelli, M. (2024). Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet, 404(10458), 1107-1118.

Adam, R. (2007). Colorectal cancer with synchronous liver metastases. British Journal of Surgery, 94(2), 129-31.

Angelsen, J. H., Horn, A., Sorbye, H., Eide, G. E., Løes, I. M., & Viste, A. (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery, 104(5), 580-589.

Björk, D., Hasselgren, K., Røsok, B. I., Larsen, P. N., Sparrelid, E., Lindell, G., Schultz, N. A., Bjørnbeth, B. A., ... Sandström, P. (2024). Long-Term Follow-Up of Patients with Advanced Colorectal Liver Metastasis: A Survival Analysis from the Randomized Controlled Multicenter Trial LIGRO. Annals of surgery open, 5(3), e455.

Bonanni, L., De'liguori Carino, N., Deshpande, R., Ammori, B. J., Sherlock, D. J., Valle, J. W., Tam, E., & O'Reilly, D. A. (2014). A comparison of diagnostic imaging modalities for colorectal liver metastases. European Journal of Surgical Oncology, 40(5), 545-50.

Bond, M. J. G., Bolhuis, K., Loosveld, O. J. L., de Groot, J. W. B., Droogendijk, H., Helgason, H. H., Hendriks, M. P., Klaase, J. M., ... Punt, C. J. A. (2023). First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. The Lancet. Oncology, 24(7), 757-771.

Bond, M. J. G., Bolhuis, K., Loosveld, O. J. L., de Groot, J. W. B., Droogendijk, H., Helgason, H. H., Hendriks, M. P., Klaase, J. M., ... Punt, C. J. A. (2025). First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. JAMA oncology, 11(1), 36-45.

Brudvik, K. W., Bains, S. J., Seeberg, L. T., Labori, K. J., Waage, A., Taskén, K., Aandahl, E. M., & Bjornbeth, B. A. (2013). Aggressive treatment of patients with metastatic colorectal cancer increases survival: a scandinavian single-center experience. HPB Surgery, 2013, 727095.

Cartwright, T. H. (2012). Treatment decisions after diagnosis of metastatic colorectal cancer. Clinical Colorectal Cancer, 11(3), 155-66.

Dueland, S., Smedman, T. M., Syversveen, T., Grut, H., Hagness, M., & Line, P. D. (2023). Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial. JAMA Surgery, 158(9), e232932.

Folprecht, G., Gruenberger, T., Bechstein, W., Raab, H. R., Weitz, J., Lordick, F., Hartmann, J. T., Stoehlmacher-Williams, J., ... Kohne, C. H. (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Annals of Oncology, 25(5), 1018-25.

Fretland, Å. A., Dagenborg, V. J., Bjørnelv, G. M. W., Kazaryan, A. M., Kristiansen, R., Fagerland, M. W., Hausken, J., Tønnessen, T. I., ... Edwin, B. (2018). Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. Annals of Surgery, 267(2), 199-207.

Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F., & Gruenberger, T. (2008). Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. Journal of Clinical Oncology, 26(11), 1830-5.

Higgins, H., & Berger, D. L. (2006). RFA for liver tumors: does it really work?. Oncologist, 11(7), 801-808.

Jones, R. P., Hamann, S., Malik, H. Z., Fenwick, S. W., Poston, G. J., & Folprecht, G. (2014). Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. European Journal of Cancer, 50(9), 1590-601.

Kanemitsu, Y., Shitara, K., Mizusawa, J., Hamaguchi, T., Shida, D., Komori, K., Ikeda, S., Ojima, H., ... Fukuda, H. (2021). Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. Journal of Clinical Oncology, 39(10), 1098-1107.

Kishi, Y., Zorzi, D., Contreras, C. M., Maru, D. M., Kopetz, S., Ribero, D., Motta, M., Ravarino, N., ... Vauthey, J. N. (2010). Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of Surgical Oncology, 17(11), 2870-6.

Ko, S., Jo, H., Yun, S., Park, E., Kim, S., & Seo, H. I. (2014). Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World Journal of Gastroenterology, 20(2), 525-31.

Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., ... Grothey, A. (2009). Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. The oncologist, 14(9), 862-70.

Larsen, I. K. (2021). Cancer in Norway 2020: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Lassen, K., Nymo, L. (2019). Norsk register for gastrokirurgi-NoRGast: årsrapport for 2018 med plan for forbedringstiltak Tromsø: Norsk register for gastrokirurgi. Hentet fra https://unn.no/Documents/Kvalitetsregistre/Norsk%20Register%20for%20Gastrokirurgi/%C3%85rsrapporter/%C3%85rsrapport%20NoRGast_2018.pdf

Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., ... Falcone, A. (2014). Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New England Journal of Medicine, 371(17), 1609-18.

Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Del Monte, F., ... Falcone, A. (2010). Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, 11(9), 845-52.

Muhi, A., Ichikawa, T., Motosugi, U., Sou, H., Nakajima, H., Sano, K., Sano, M., Kato, S., ... Araki, T. (2011). Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. Journal of Magnetic Resonance Imaging, 34(2), 326-35.

Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., ... Gruenberger, T. (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology, 14(12), 1208-15.

Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., ... Federation Francophone de Cancerologie, D. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 371(9617), 1007-16.

Portier, G., Elias, D., Bouche, O., Rougier, P., Bosset, J. F., Saric, J., Belghiti, J., Piedbois, P., ... Bedenne, L. (2006). Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. Journal of Clinical Oncology, 24(31), 4976-82.

Robinson, S. M., Wilson, C. H., Burt, A. D., Manas, D. M., & White, S. A. (2012). Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Annals of Surgical Oncology, 19(13), 4287-99.

Sahani, D. V., Bajwa, M. A., Andrabi, Y., Bajpai, S., & Cusack, J. C. (2014). Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Annals of Surgery, 259(5), 861-72.

Sandström, P., Røsok, B. I., Sparrelid, E., Larsen, P. N., Larsson, A. L., Lindell, G., Schultz, N. A., Bjørnbeth, B. A., ... Björnsson, B. (2018). ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Annals of Surgery, 267(5), 833-840.

Selzner, M., Hany, T. F., Wildbrett, P., McCormack, L., Kadry, Z., & Clavien, P. A. (2004). Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Annals of Surgery, 240(6), 1027-1034.

Sorbye, H., Mauer, M., Gruenberger, T., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., ... Federation Francophone de Cancerologie, D. (2012). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Annals of Surgery, 255(3), 534-9.

Stoltz, A., Gagniere, J., Dupre, A., & Rivoire, M. (2014). Radiofrequency ablation for colorectal liver metastases. Journal of Visceral Surgery, 151 Suppl 1, S33-44.

Storli, P. E., Johnsen, G., Juel, I. S., Grønbech, J. E., & Bringeland, E. A. (2019). Impact of increased resection rates and a liver parenchyma sparing strategy on long-term survival after surgery for colorectal liver metastases. A population-based study. Scandinavian Journal of Gastroenterology, 54(7), 890-898.

Søreide, J. A., Eiriksson, K., Sandvik, O., Viste, A., Horn, A., Johnsen, G., & Grønbech, J. E. (2008). Kirurgisk behandling av levermetastaser fra kolorektal kreft. Tidsskrift for den Norske Legeforening, 128(1), 50-3.

Tanis, E., Nordlinger, B., Mauer, M., Sorbye, H., van Coevorden, F., Gruenberger, T., Schlag, P. M., Punt, C. J., ... Ruers, T. J. (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer, 50(5), 912-9.

Thelen, A., Jonas, S., Benckert, C., Schumacher, G., Lopez-Hanninen, E., Rudolph, B., Neumann, U., & Neuhaus, P. (2007). Repeat liver resection for recurrent liver metastases from colorectal cancer. European Journal of Surgical Oncology, 33(3), 324-8.

Torkzad, M. R., Riddell, A. M., Chau, I., Cunningham, D., & Koh, D. M. (2021). Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. AJR. American journal of roentgenology, 216(3), 669-676.

van der Lei, S., Puijk, R. S., Dijkstra, M., Schulz, H. H., Vos, D. J. W., De Vries, J. J. J., Scheffer, H. J., Lissenberg-Witte, B. I., ... Meijerink, M. R. (2025). Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. The Lancet. Oncology, 26(2), 187-199.

Wicherts, D. A., de Haas, R. J., Salloum, C., Andreani, P., Pascal, G., Sotirov, D., Adam, R., Castaing, D., & Azoulay, D. (2013). Repeat hepatectomy for recurrent colorectal metastases. British Journal of Surgery, 100(6), 808-18.

Wiering, B., Krabbe, P. F., Jager, G. J., Oyen, W. J., & Ruers, T. J. (2005). The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer, 104(12), 2658-70.